Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1285487

registered interest
date	10/02/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Clean Steel Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what progress he has made on implementing the Clean Steel Fund.
tabling member constituency	Greenwich and Woolwich
tabling member printed	Matthew Pennycook
uin	152593
answer	answer is ministerial correction date of answer 22/02/2021 answer text <p>In August 2019, the Government announced a £250 million Clean Steel Fund to support the UK steel sector to transition to lower carbon iron and steel production, through investment in new technologies and processes. The Fund will help the sector towards achieving our target of net zero emissions by 2050, by maximising longevity and resilience while harnessing clean growth opportunities.</p><p> </p><p>Steel industry stakeholders provided positive responses to our Call for Evidence. A summary of the responses was published in December 2020 and will inform the scheme’s design. As we develop the Fund, we will continue to engage closely with the sector to ensure that it meets the needs of businesses.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 22/02/2021 16:41:22 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4520 label Biography information for Matthew Pennycook

1285737

registered interest
date	10/02/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Buses: Manufacturing Industries
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what steps he is taking to support bus manufacturing in the UK; and when he or his Ministerial team last met with representatives of UK bus manufacturers.
tabling member constituency	Nottingham South
tabling member printed	Lilian Greenwood
uin	152506
answer	answer is ministerial correction date of answer 22/02/2021 answer text <p>My noble Friend Lord Grimstone recently met with representatives of bus manufacturers at an automotive sector roundtable on 10 February.</p><p> </p><p>The Government is continuing its longstanding programme of support to ensure that the UK automotive sector remains at the forefront of technological developments. Government and Industry have jointly committed almost £1.5 billion through the Advanced Propulsion Centre and Faraday Battery Challenge to support the research, development, and manufacture of zero and low-emission technologies. The Advanced Propulsion Centre is supporting a number of projects aimed at developing technologies to reduce emissions in bus applications.</p><p> </p><p>In addition, as part of my Rt. Hon. Friend the Prime Minister’s 10 Point Plan for a green industrial revolution, nearly £500m of funding for the Automotive Transformation Fund will be made available in the next four years to build an internationally competitive electric vehicle supply chain.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 22/02/2021 17:16:02 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4029 label Biography information for Lilian Greenwood

1285752

registered interest
date	10/02/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Batteries: Factories
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what recent discussions he has had with private developers on proposals to build a battery factory in (a) Wales and (b) elsewhere in the UK.
tabling member constituency	Dwyfor Meirionnydd
tabling member printed	Liz Saville Roberts
uin	152596
answer	answer is ministerial correction date of answer 22/02/2021 answer text <p>The Government remains committed to securing UK gigafactories.</p><p> </p><p>Ministers and Officials in the Department are regularly engaging with potential investors. These discussions are ongoing, and it would not be appropriate for me to comment on specific cases.</p><p> </p><p>There are a range of factors that will influence the location of any UK gigafactory investment, and ultimately this decision will be a commercial matter. There are several locations across the UK that may meet the requirements of investors, including in Wales.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 22/02/2021 17:14:35 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4521 label Biography information for Liz Saville Roberts

1285155

registered interest
date	09/02/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans his Department has to monitor the effectiveness of different covid-19 vaccines on different age groups.
tabling member constituency	Rother Valley
tabling member printed	Alexander Stafford
uin	151889
answer	answer is ministerial correction date of answer 19/02/2021 answer text <p>Public Health England is leading on the surveillance of the COVID-19 vaccine programme and has developed a surveillance strategy to monitor the effectiveness of COVID-19 vaccines against mortality, hospitalisations, confirmed infections, markers of infectiousness and the impact on transmission.</p><p> </p><p>Whilst phase three clinical trials provided evidence of vaccine effectiveness against symptomatic disease, further evidence is needed on how effectiveness varies by subgroup, including by age. This will be done using advanced surveillance techniques once the earliest eligible cohorts have been offered a full course of vaccination.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi grouped question UIN 151688 151745 151855 question first answered 19/02/2021 10:40:36 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4866 label Biography information for Alexander Stafford

1285176

registered interest
date	09/02/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what recent assessment he has made of the adequacy of the resources available to vaccine manufacturers seeking to keep up with emerging variants of covid-19.
tabling member constituency	Newport West
tabling member printed	Ruth Jones
uin	151843
answer	answer is ministerial correction date of answer 17/02/2021 answer text <p>The Government is undertaking laboratory work as a priority to better understand the impact of the new Covid-19 variants on the vaccines currently in deployment, in particular the risk of vaccine resistance. We maintain close contact with vaccine developers to understand their efficacy studies of their vaccines on variants and the impact on current supply chain arrangements for their manufacture.</p><p> </p><p>We continue to take a portfolio-based approach that monitors the landscape of Covid-19 vaccine development and we remain confident that the three vaccines (Pfizer/BioNTech, Oxford University/AstraZeneca, and Moderna) that we have purchased, which have been authorised by the Medicines and Healthcare products Regulatory Agency, will continue to be effective against the virus.</p><p> </p><p>The Government has also established a new partnership with the vaccine manufacturer, CureVac, to rapidly develop new vaccines in response to new Covid-19 variants, should this be needed. The new agreement will utilise UK expertise on genomics and virus sequencing to allow new varieties of vaccines based on messenger RNA technology to be developed quickly against new strains of Covid-19 if they are needed. An initial order has been made for 50 million doses.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 17/02/2021 15:59:17 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4716 label Biography information for Ruth Jones

1285207

registered interest
date	09/02/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans his Department has to monitor the effectiveness of different covid-19 vaccines on different age groups.
tabling member constituency	Ellesmere Port and Neston
tabling member printed	Justin Madders
uin	151745
answer	answer is ministerial correction date of answer 19/02/2021 answer text <p>Public Health England is leading on the surveillance of the COVID-19 vaccine programme and has developed a surveillance strategy to monitor the effectiveness of COVID-19 vaccines against mortality, hospitalisations, confirmed infections, markers of infectiousness and the impact on transmission.</p><p> </p><p>Whilst phase three clinical trials provided evidence of vaccine effectiveness against symptomatic disease, further evidence is needed on how effectiveness varies by subgroup, including by age. This will be done using advanced surveillance techniques once the earliest eligible cohorts have been offered a full course of vaccination.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi grouped question UIN 151688 151855 151889 question first answered 19/02/2021 10:40:36 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4418 label Biography information for Justin Madders

1285211

registered interest
date	09/02/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans his Department has to monitor the effectiveness of different covid-19 vaccines on different age groups.
tabling member constituency	Ashfield
tabling member printed	Lee Anderson
uin	151855
answer	answer is ministerial correction date of answer 19/02/2021 answer text <p>Public Health England is leading on the surveillance of the COVID-19 vaccine programme and has developed a surveillance strategy to monitor the effectiveness of COVID-19 vaccines against mortality, hospitalisations, confirmed infections, markers of infectiousness and the impact on transmission.</p><p> </p><p>Whilst phase three clinical trials provided evidence of vaccine effectiveness against symptomatic disease, further evidence is needed on how effectiveness varies by subgroup, including by age. This will be done using advanced surveillance techniques once the earliest eligible cohorts have been offered a full course of vaccination.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi grouped question UIN 151688 151745 151889 question first answered 19/02/2021 10:40:36 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4743 label Biography information for Lee Anderson

1285238

registered interest
date	09/02/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to UK Covid-19 Vaccines Delivery Plan published on 11 January 2021, what the timetable is for the use of the mobile model to deliver the covid-19 vaccine to people experiencing homelessness.
tabling member constituency	Lancaster and Fleetwood
tabling member printed	Cat Smith
uin	151756
answer	answer is ministerial correction date of answer 17/02/2021 answer text <p>The Government is following the independent advice of the Joint Committee on Vaccination and Immunisation (JCVI), which agrees priority groupings for vaccine. Anyone who is homeless and falls into these groups is eligible for the vaccine and we are working closely with partners to ensure they can access it. NHS England and NHS Improvement are working with voluntary community and social enterprise partners, inclusion health providers and others to develop an accessible model for delivery of the vaccine to people from inclusion health populations. As a result of having two vaccines now deployable, we are considering a number of options and will co-design these with partners based on the different local and logistical considerations.</p><p> </p><p>In the immediate period we are asking partners to support their clients and service users to register with a general practice, where they are not already and if they have health conditions that would make them clinically vulnerable/clinically extremely vulnerable that this is recorded to ensure they receive the vaccine in line with the JCVI’s advice on prioritisation. Over the coming weeks we will consider a range of possible delivery models, including mobile models, to ensure all those prioritised in accordance with the JCVI’s advice receive the vaccine at the appropriate time regardless of their circumstance.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 17/02/2021 16:39:52 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4436 label Biography information for Cat Smith

1285358

registered interest
date	09/02/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans his Department has to monitor the effectiveness of different covid-19 vaccines in different age groups.
tabling member constituency	Hendon
tabling member printed	Dr Matthew Offord
uin	151688
answer	answer is ministerial correction date of answer 19/02/2021 answer text <p>Public Health England is leading on the surveillance of the COVID-19 vaccine programme and has developed a surveillance strategy to monitor the effectiveness of COVID-19 vaccines against mortality, hospitalisations, confirmed infections, markers of infectiousness and the impact on transmission.</p><p> </p><p>Whilst phase three clinical trials provided evidence of vaccine effectiveness against symptomatic disease, further evidence is needed on how effectiveness varies by subgroup, including by age. This will be done using advanced surveillance techniques once the earliest eligible cohorts have been offered a full course of vaccination.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi grouped question UIN 151745 151855 151889 question first answered 19/02/2021 10:40:36 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4006 label Biography information for Dr Matthew Offord

1284773

registered interest
date	08/02/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, when he plans to publish the (a) scientific evidence and (b) his rationale for his Department's policy to extend the gap between covid-19 vaccine doses to 12 weeks.
tabling member constituency	Streatham
tabling member printed	Bell Ribeiro-Addy
uin	150943
answer	answer is ministerial correction date of answer 16/02/2021 answer text <p>Estimates of efficacy of the first dose of COVID-19 vaccines and the rationale for the advice from the Joint Committee on Vaccination and Immunisation is available in the statement published on 31 December which is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement/optimising-the-covid-19-vaccination-programme-for-maximum-short-term-impact" target="_blank">https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement/optimising-the-covid-19-vaccination-programme-for-maximum-short-term-impact</a></p><p>Further supporting data has since been published on the AstraZeneca vaccine, which indicate high vaccine efficacy from the first dose of vaccine and better immune responses from the second dose with an extended schedule of up to 12 weeks. Data indicates protection from the first dose is maintained over a twelve-week period. This information is available at the following link:</p><p><a href="https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3777268" target="_blank">https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3777268</a></p><p>The United Kingdom Chief Medical Officers wrote to the medical profession regarding the COVID-19 vaccination programmes, stating that setting out a model where vaccinating twice the number of people in the next two to three months provides greater public health protection. The letter is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/letter-to-the-profession-from-the-uk-chief-medical-officers-on-the-uk-covid-19-vaccination-programmes/letter-to-the-profession-from-the-uk-chief-medical-officers-regarding-the-uk-covid-19-vaccination-programmes" target="_blank">https://www.gov.uk/government/publications/letter-to-the-profession-from-the-uk-chief-medical-officers-on-the-uk-covid-19-vaccination-programmes/letter-to-the-profession-from-the-uk-chief-medical-officers-regarding-the-uk-covid-19-vaccination-programmes</a></p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 16/02/2021 17:10:13 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4764 label Biography information for Bell Ribeiro-Addy